Cellectar Biosciences Inc (CLRB)

[CashMoneyNY]

Looks very promising cant wait till January. “This patent provides intellectual property protection for one of our most interesting paclitaxel PDCs,” said Jim Caruso, president and CEO of Cellectar. “The chemotherapeutic conjugate program is an exciting addition to CLR 131, our lead radiotherapeutic PDC currently in a Phase I clinical study for relapsed or refractory multiple myeloma. We plan to initiate a Phase II trial for CLR 131 in patients with relapsed or refractory multiple myeloma and select hematologic malignancies in early 2017. We are enthusiastic about the potential of each of these programs and look forward to reporting continued progress.”